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POLYMERASE CHAIN REACTION: ADVANTAGES AND DRAWBACKS 
 
Prof. Dr. Claude Favrot 
Vetsuisse Faculty in Zurich 
 
Polymerase chain reaction (PCR) was first described in 1985 and is nowadays one of 
the most frequently used tools not only by researchers but also by practitioners. It is 
probably one of the best examples of a technique that jumped from “the bench to the 
bedside”! Every practitioner should now be aware of the advantages but also of the 
limitations of this tool to be able to use it properly. 
 
BASICS TO GET STARTED: 
PCR uses short segments of nucleotides, called primers. The sequences of these 
primers are complementary to the sequences of the target (microbe nucleic acids). The 
primers serve as templates upon which a new DNA molecule can be synthesized. They 
may be of variable length but are usually 15-30bp long. The primers are added to a 
solution of containing a DNA polymerase, each of the four nucleotides and a source of 
DNA containing the target sequence. The solution is heated to denaturate the DNA 
(separate into its two strands), then cooled to let primers bind to complementary regions 
on the target DNA.  The solution is subsequently heated again to promote DNA 
extension (addition of nucleotides to 
the primers ends). The product is 
consequently a sequence of DNA 
delimited by the two primers and 
strictly identical to the target DNA. 
The solution will be submitted to 25 
to 40 cycles (amplification). The 
whole reaction results in an 
accumulation of millions of copies of 
the target DNA. Confirmation of the 
correctly sized amplified DNA product is usually carried 
out by agarose gel electrophoresis. The picture on the 
right is one typical example of the end-point PCR: two 
different sets of primers were used (PAPF and CP4) 
and three samples were tested (22,24,39). With the first 
set of primers, all samples were negative while, with the 
second one, sample 24 was positive.  
 
MATERIAL 
 
PCR is a powerful tool to amplify minute amounts of nucleic acids. Due to its 
unprecedented sensitivity, the method has become an essential diagnostic and 
research tool for infectious dermatology. Additionally, PCR can be used on all tissues or 
samples (fresh tissues, paraffin-embedded tissues, blood, feces etc…). It is also 
possible to analyze samples of poor conditions because only relatively short intact 
sequences of DNA are required. Archival materials can consequently be used for 
retrospective studies. In this latter case, however, amplification depends on the 
conservation of the target DNA. It has, for example, been demonstrated that DNA could 
be spoiled by long-stay in formalin and that amplification subsequently failed.  
 
PCR HAS SOME LIMITATIONS…. 
 
PCR is not only a very sensitive technique but also a very specific one: The primers are 
usually directly complementary to the target sequence and DNA can only be amplified if 
the matching target DNA-primer is adequate. In fact, as primers are directly 
complementary to target DNA, amplification only occurs if the target is exactly or closely 
related to the DNA sequence of the expected causative agent. For example, primers 
designed to amplify canine oral papillomavirus DNA will probably not amplify the DNA of 
another canine papillomavirus. PCR demands that sequence information be available 
for at least a part of the DNA that is to be amplified.  
Interpreting the clinical relevance of a positive PCR amplification can also be 
challenging. In fact some extremely sensitive nested PCR detect even 0.05 viral 
genome copy per cell. The presence of such trace amounts of DNA does not indicate a 
clinical infection but probably a latent or clinically non-relevant infection. For this reason, 
one must interpret cautiously some PCR results. 
Last but not least, PCR does not allow localization of the nucleic acids. It is 
consequently not possible to differentiate a clinical infection from a contamination. It 
has, for example been shown, that papillomavirus DNA can be amplified from virtually 
each sample of normal human skin. But the detection rate is much lower when the 
stratum corneum of these samples is removed. This indicates that most of these 
papillomavirus are probably contaminant.  
 
BUT IT IS NOT THAT BAD: THERE IS ALWAYS A SOLUTION! 
PCR cannot amplify RNA… 
As PCR cannot amplify RNA, detection of RNA is carried out through reverse-
transcriptase PCR (RT-PCR). The enzyme reverse transcriptase allows synthesis of 
cDNA from a RNA template. PCR is subsequently carried out, using cDNA as target 
DNA. 
 
PCR only amplifies specific targets… 
To circumvent this drawback degenerate or consensus primers can be designed: 
Such primers allow the amplification of nucleic acids of multiple related infectious agents 
(Some degenerated primers are able to amplify nucleic acids of up to 70 human 
papillomaviruses, for example).  
 
 
PCR amplifies only a very limited part of the genome… 
That is true but it is also possible, in some instances, to carry out the reaction with 
several set of primers: Multiplex PCR consists of multiple primer sets within a single 
PCR mixture to produce amplicons of varying sizes that are specific to different DNA 
sequences. By targeting multiple genes at once, additional information may be gained 
from a single test-run that otherwise would require several times the reagents and more 
time to perform. Annealing temperatures for each of the primer sets must be optimized 
to work correctly within a single reaction, and amplicon sizes. That is, their base pair 
length should be different enough to form distinct bands when visualized by gel 
electrophoresis.  
 
PCR may sometimes not be specific enough… 
That is the reason why nested PCR were developed! In fact, nested PCR increases the 
specificity of DNA amplification, by reducing background due to non-specific 
amplification of DNA. Two sets of primers are used in two successive PCRs. In the first 
reaction, one pair of primers is used to generate DNA products, which besides the 
intended target, may still consist of non-specifically amplified DNA fragments. The 
product(s) are then used in a second PCR with a set of primers whose binding sites are 
completely or partially different from and located 3' of each of the primers used in the 
first reaction. Nested PCR is often more successful in specifically amplifying long DNA 
fragments than conventional PCR, but it requires more detailed knowledge of the target 
sequences. 
 
PCR is not quantitative… 
But it can be… Real-time PCR (qPCR; RT should be reserved for Reverse 
Transcriptase and Real Time should be noted Q for quantitative!) has been 
developed to estimate nucleic acids concentration within the samples. qPCR is used to 
measure the quantity of a target sequence (commonly in real-time). It quantitatively 
measures starting amounts of DNA, cDNA, or RNA. Quantitative PCR is commonly 
used to determine whether a DNA sequence is present in a sample and the number of 
its copies in the sample. Quantitative PCR has a very high degree of precision. 
Quantitative PCR methods use fluorescent dyes, such as Sybr Green, EvaGreen or 
fluorophore-containing DNA probes, such as TaqMan, to measure the amount of 
amplified product in real time. In the last few years, in example, such procedure were 
used in two different studies to assess the expression of thymic stromal lymphopoietin 
(TSLP) and fillagrin, respectively, in skin samples retrieved from dogs with atopic 
dermatitis. For such studies a reference gene should be used, 
whose expression is stable and consistent in canine skin. In 
the drawing above, one should imagine that A is the curve of the reference gene and B 
the curve of the studied genes: as the exponential phase of the reaction begin with less 
cycles (in this case, n:10) than for the reference gene (n:15), we can conclude that the 
studied gene is expressed more than the reference gene. If the expression of the 
reference gene is known, expression of the studied one can be computed. 
 
It is not possible to know where the DNA was in the sample… 
In situ hybridization can be regarded as a combination of PCR and immunochemistry 
and allows cellular localization of the target DNA. Basically, PCR is used to generate 
dye-associated primers that will serve 
subsequently for the immunochemistry. We 
have used this tool to demonstrate that viral 
DNA was present in the koilocytes of early 
stages of penis carcinomas in horses. On the left part of the picture, we can see the 
koilocytes and on the right part, we see that these koilocytes harbor the viral DNA 
(brown staining). 
 
PCR FROM BENCH TO BEDSIDE: WONDERFUL BUT…. BE CAREFUL! 
 
As mentioned above, PCR is a wonderful tool for research but also for daily diagnosis. 
One should however be aware of one possible pitfall: the sensitivity of the method. As 
already said, some very sensitive PCR settings may be able to identify as few as one 
genome copy within 100 cells! It is very unlikely that these few microorganisms may 
cause any damage to the host but… the test is positive! One should consequently 
interpret PCR results cautiously. Exactly like the IgE serology tests that identify 
sensitization (and not allergy!), PCR identifies infection, but does not say anything on 
the actual link between this infection and the clinical signs. Let’s take the example of 
leishmaniasis! 
Before 2000, most authors agreed that the prevalence of the disease was from 1 to 15% 
in endemic areas of Europe. But, as soon as PCR studies began, data changed. It was 
suddenly obvious that the great majority of dogs, if not all, living in endemic areas were 
infected. But only some of them were seropositive and few presented with clinical signs!  
That is the reason why PCR is NOT a good test to assess whether leishmania infection 
explain the clinical signs of one specific dog. The gold standard to answer this question 
remains the detection of leishmania-specific IgG! 
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